**Author details**

Michael J. Stones\*, Sarah Worobetz, Jason Randle, Carlina Marchese, Shauna Fossum, Dane Ostrom and Peter Brink Lakehead University, Thunder Bay, Ontario, Canada

\*Address all correspondence to: mstones@lakeheadu.ca

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**21**

*Psychotropic Medication Use and Mortality in Long-Term Care Residents*

in US nursing homes. Journal of the American Geriatrics Society. 2003;**51**(10):1404-1409. DOI: 10.1046/j.1532-5415.2003.51458.x

[8] Neufeld E, Freeman S, Joling K, Hirdes JP. "When the golden years are blue" Changes in depressive symptoms over time among older adults newly admitted to long-term care facilities. Clinical Gerontologist. 2014;**37**(3):298-315. DOI: 10.1080/07317115.2014.885919

[9] Hirdes JP, Poss JW, Mitchell L, Korngut L, Heckman G. Use of the interRAI CHESS scale to predict mortality among persons with neurological conditions in three care settings. PLoS One. 2014;**9**(6):e99066. DOI: 10.1371/journal.pone.0099066

[10] Worobetz S. Effects of antipsychotic

Thunder Bay: Lakehead University; 2014

Cooper T, et al. Frequency of and factors related to pro re nata (PRN) medication use in aged care services. Research in Social and Administrative Pharmacy. 2018;**14**(10):964-967. DOI: 10.1016/j.

[12] La Frenais FL, Bedder R, Vickerstaff V, Stone P, Sampson EL. Temporal trends in analgesic use in long-term care facilities: A systematic review of international prescribing. Journal of the American Geriatrics Society. 2018;**66**(2):376-382.

[13] Holmerová I, Auer SR, Beránková A,

Höfler M, Ratajczak P, Šteffl M. Cognitive status and use of analgesics and anxiolytics in residents of nursing homes in the Czech Republic. Clinical Interventions in Aging. 2018;**13**:2511.

DOI: 10.2147/CIA.S18860

medications on older adults with dementia in Canadian complex and long-term care facilities [thesis].

[11] Stasinopoulos J, Bell JS, Ryan-Atwood TE, Tan EC, Ilomäki J,

sapharm.2017.11.004

DOI: 10.1111/jgs.15238

*DOI: http://dx.doi.org/10.5772/intechopen.85971*

[1] Kozman MN, Wattis J, Curran S. Pharmacological management of behavioural and psychological disturbance in dementia. Human Psychopharmacology: Clinical and Experimental. 2006;**21**(1):1-2. DOI:

[2] Cerejeira J, Lagarto L, Mukaetova-

psychological symptoms of dementia. Frontiers in Neurology. 2012;**3**:73. DOI:

[3] Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2003;**27**(7):1081- 1090. DOI: 10.1016/j.pnpbp.2003.09.004

[4] Prakash S, Masand MD. Side effects of antipsychotics in the elderly. The Journal of Clinical Psychiatry.

[5] Banerjee S. The Use of Antipsychotic Medication for People with Dementia: Time for Action. London: Department of Health, UK Government; 2009. Available from:http://psychrights.

2000;**61**:43-49

org/research/digest/nlps/

10.3233/ADR-170042

banerjeereportongeriatricRalph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: Updated review and meta-analysis in dementia and general mental health care. Journal of Alzheimer's Disease Reports. 2018;**2**(1):287-312. DOI:

[6] Brink P, Stewart S, Stones MJ. Institutional reactions to verbally abusive behaviour by residents of longterm care facilities. In: Proceedings of the Annual Conference of the Ontario Network for the Prevention of Elder

Abuse. Toronto, ON; 2005

[7] Jones RN, Marcantonio ER, Rabinowitz T. Prevalence and correlates of recognized depression

Ladinska E. Behavioral and

10.3389/fneur.2012.00073

10.1002/hup.745

**References**

*Psychotropic Medication Use and Mortality in Long-Term Care Residents DOI: http://dx.doi.org/10.5772/intechopen.85971*
